JP2024522272A5 - - Google Patents
Info
- Publication number
- JP2024522272A5 JP2024522272A5 JP2023572540A JP2023572540A JP2024522272A5 JP 2024522272 A5 JP2024522272 A5 JP 2024522272A5 JP 2023572540 A JP2023572540 A JP 2023572540A JP 2023572540 A JP2023572540 A JP 2023572540A JP 2024522272 A5 JP2024522272 A5 JP 2024522272A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA202170290 | 2021-06-04 | ||
| DKPA202170290 | 2021-06-04 | ||
| PCT/EP2022/065217 WO2022254021A1 (en) | 2021-06-04 | 2022-06-03 | Antisense oligonucleotides targeting adenosine kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024522272A JP2024522272A (ja) | 2024-06-13 |
| JP2024522272A5 true JP2024522272A5 (https=) | 2025-07-07 |
| JPWO2022254021A5 JPWO2022254021A5 (https=) | 2025-07-07 |
Family
ID=82196319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572540A Pending JP2024522272A (ja) | 2021-06-04 | 2022-06-03 | アデノシンキナーゼを標的とするアンチセンスオリゴヌクレオチド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240240188A1 (https=) |
| EP (1) | EP4347824A1 (https=) |
| JP (1) | JP2024522272A (https=) |
| CN (1) | CN117642505A (https=) |
| AU (1) | AU2022287241A1 (https=) |
| WO (1) | WO2022254021A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3228833A1 (en) * | 2021-08-19 | 2023-02-23 | Neumirna Therapeutics Aps | Antisense oligonucleotides targeting adenosine kinase |
| WO2026068729A1 (en) * | 2024-09-26 | 2026-04-02 | Neumirna Therapeutics Aps | Antimir-27b for treatment of parkinson's disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
| CN1350542A (zh) | 1999-03-18 | 2002-05-22 | 埃克西库恩公司 | 木－lna类似物 |
| JP4768132B2 (ja) | 1999-03-24 | 2011-09-07 | エクシコン エ／エス | ［２．２．１］ビシクロヌクレオシドの改良された製法 |
| IL148916A0 (en) | 1999-10-04 | 2002-09-12 | Exiqon As | Design of high affinity rnase h recruiting oligonucleotide |
| JP4413493B2 (ja) | 2000-10-04 | 2010-02-10 | サンタリス ファーマ アー／エス | プリンｌｎａ類似体の改善された合成方法 |
| AU2002328792A1 (en) | 2001-07-12 | 2003-01-29 | Santaris Pharma A/S | Method for preparation of lna phosphoramidites |
| JP4476802B2 (ja) | 2002-05-08 | 2010-06-09 | サンタリス ファーマ アー／エス | ロックト核酸誘導体の製造 |
| US7481672B2 (en) | 2005-07-21 | 2009-01-27 | Rosemount Tank Radar Ab | Dielectric connector, DC-insulating through-connection and electronic system |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| CA2648132C (en) | 2006-04-03 | 2019-05-28 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| CN104136451A (zh) | 2011-09-07 | 2014-11-05 | 玛瑞纳生物技术有限公司 | 具有构象限制的单体的核酸化合物的合成和用途 |
| WO2013067451A2 (en) * | 2011-11-04 | 2013-05-10 | Population Diagnostics Inc. | Methods and compositions for diagnosing, prognosing, and treating neurological conditions |
| KR20160083876A (ko) | 2013-11-14 | 2016-07-12 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | ApoB 안티센스 접합체 화합물 |
| TWI864340B (zh) | 2014-10-10 | 2024-12-01 | 美商艾爾妮蘭製藥公司 | 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法 |
-
2022
- 2022-06-03 JP JP2023572540A patent/JP2024522272A/ja active Pending
- 2022-06-03 AU AU2022287241A patent/AU2022287241A1/en active Pending
- 2022-06-03 CN CN202280039858.1A patent/CN117642505A/zh active Pending
- 2022-06-03 EP EP22733330.9A patent/EP4347824A1/en active Pending
- 2022-06-03 WO PCT/EP2022/065217 patent/WO2022254021A1/en not_active Ceased
- 2022-06-03 US US18/565,432 patent/US20240240188A1/en active Pending